超声造影在肝细胞癌诊断及治疗中的应用进展

doi:10.3969/j.issn.1672-5069.2011.02.034

摘要/Abstract

摘要： 随着影像学技术的发展，超声造影作为新型影像诊断技术，能显著提高对肝脏局灶病变的诊断能力及提高肝癌诊断的敏感性和特异性，在临床上广泛应用于肝癌的定性诊断及疗效评估。本文重点介绍超声造影在肝细胞癌诊治中的应用。

吴秀栓,李建生,许戈良,马金良,荚卫东. 超声造影在肝细胞癌诊断及治疗中的应用进展[J]. 实用肝脏病杂志, 2011, 14(2): 158-160.

[1] GRAMIAK R，SHAH PM，KRAMER DH. Ultrasound cardiography:contrast studies in anatomy and function[J]. Radiology， 1969，92（5）:939-948.
[2] MATSUDA Y，YABUUCHI I. Hepatic tumors:US contrast enhancement with CO2 microbubbles[J]. Radiology，1986，161（3）:701-705.
[3] LEEN E，ANGERSON WJ，YARMENITIS S，et al. Multi-centre clinical study evaluating the efficacy of SonoVue，a new ultrasound contrast agent in Doppler investi- gation of focal hepatic lesions[J]. Eur J Radiol，2002，41（3）:200-206.
[4] ALBRECHT T，BLOMLEY M，BOLONDI L，et al. Guidelines for the use of contrast agents in ultrasound[J]. Ultraschall Med，2004，25（4）:249-256.
[5] QUAIA E，CALLIADA F，BERTOLOTTO M，et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride filled microbubble contrast agent:diagnostic performance and confidence[J]. Radiology，2004，232（2）:420-430.
[6] FAN ZH，CHEN MH，DAI Y，et al. Evaluation of the primary malignancies in the liver using contrast-enhanced sonography:correlation with pathology[J]. Am J Roentgenol，2006，186（6）:1512-1519.
[7] WILSON SR，BURNS PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography[J]. Am J Roentgenol，2006，186（5）:1401-1412.
[8] LEEN E，CECCOTTI P，KALOGEROPOULOU C，et al. Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography[J]. Am J Roentgenol，2006，186（6）:1551-1559.
[9] JANG HJ，KIMTK，BURNS P，et al. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US:comparison with histologic differentiation[J]. Radiology，2007，244（3）:898-906.
[10] KIM TK，KIM AY，CHOI BI. Hepatocellular carcinoma: harmonic ultrasound and contrast agent[J]. Abdom Imaging， 2002，27（2）:129-138.
[11] LENCIONI R. Impact of European Federation of Societies for Ultrasound in Medicine and Biology（EFSUMB）guidelines on the use of contrast agents in liver ultrasound[J]. Eur Radiol，2006，16（7）:1610-1613.
[12] JANG HJ，KIM TK，WILSON SR. Small nodules（1 2cm）in liver cirrhosis:Characterization with contrast-enhanced ultrasound[J]. Eur J Radiol[J]. 2009，72（3）:418-424.
[13] JANG HJ，KIM TK，WILSON SR. Imaging of malignant liver masses: characterization and detection[J]. Ult rasound Q，2006，22（1）:19-29.
[14] 王文平，李超伦，丁红，等. 转移性肝癌的实时超声造影诊断[J]. 中华超声影像学杂志，2008，17（2）:127-129.
[15] CHEN MH，YANG W，YAN K，et a1. The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation[J]. Clin Radiol，2007，62（8）:752-760.
[16] VON HERBAY A，VOGT C，WILLERS R，et a1. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions[J]. Ultrasound Med，2004，23（12）:1557-1568.
[17] NICOLAU C，CATAL V，VILANA R，et a1. Evaluation of hepatoceIlula carcinoma using SonoVue，asecond generation ultrasound contrast agent；correlation with cellular differentiation[J]. Eur Radiol，2004，14（6）:1092-1099.
[18] LIU GJ，XU HX，LU MD，et al. Correlation between enhancement pattern of hepatocellular carcinoma on real-time contrast-enhanced ultrasound and tumour cellular differentiation on histopathology[J]. Br Jradiol，2007，80（953）:321-330.
[19] WANG WP，WU Y，LUO Y，et a1. Clinical value of contrast-enhanced ultrasonography in the characterization of focal liver lesions: a prospective multicenter trial[J]. Hepatobiliary Pancreat Dis Int，2009，8（4）:370-376.
[20] FORNER A，VILANA R，AYUSO C，et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology，2008，47（1）:97-104
[21] DAI Y，CHEN MH，FAN ZH，et a1. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis:comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography[J]. Hepatol Res，2008，38（3）:281-290.
[22] BRUIX J，SHERMAN M. Management of hepatocellular carcinoma[J]. Hepatology，2005，42（5）:1208-1236.
[23] BEATON C，COCHLIN D， KUMAR N. Contrast enhanced ultrasound should be the initial radiological investigation to characterise focal liver lesions[J]. Eur J Surg Oncol，2010，36（1）:43-46.
[24] WU H，LU Q，LUO Y，et al. Application of contrast-enhanced intraoperative ultrasonography in the decision-making about hepatocellular carcinoma operation[J]. World J Gastroenterol，2010，16（4）:508-512.
[25] SALVAGGIO G，CAMPISI A，GRECO VL，et al. Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT[J]. Abdom Imaging，2010，35（4）:447-453.
[26] RICCI P，CANTISANI V，DRUDI F，et al. Is Contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma[J]. Ultraschallin Med，2009，30（3）:252-258.
[27] NICOLAU C，VILANA R，BIANCHI L，et al. Early-stage hepatocellular carcinoma:the high accuracy of real-time contrast-enhanced ultrasonography in the assessment of response to percutaneous treatment[J]. Eur Radiol，2007，17（Suppl 6）:F80-88.

超声造影在肝细胞癌诊断及治疗中的应用进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	叶显俊, 何年安, 隋秀芳, 刘力. 二维超声和超声造影检查肝脏上皮样血管内皮瘤表现特征分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 904-907.
[3]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[4]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[5]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[6]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[7]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[8]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[9]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[10]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[11]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[12]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[13]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[14]	王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275.
[15]	赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300.